-
Je něco špatně v tomto záznamu ?
Galectin-3-Binding Protein Inhibits Extracellular Heparan 6-O-Endosulfatase Sulf-2
A. Panigrahi, J. Benicky, R. Aljuhani, P. Mukherjee, Z. Nováková, C. Bařinka, R. Goldman
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2021
Free Medical Journals
od 2002 do Před 1 rokem
Freely Accessible Science Journals
od 2002
PubMed Central
od 2008
Europe PubMed Central
od 2008 do Před 1 rokem
Open Access Digital Library
od 2002-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2002
- MeSH
- antigeny nádorové MeSH
- chondroitinsulfáty metabolismus MeSH
- dlaždicobuněčné karcinomy hlavy a krku metabolismus patologie MeSH
- heparansulfát proteoglykany metabolismus MeSH
- lidé MeSH
- nádorové biomarkery MeSH
- nádorové buněčné linie MeSH
- nádorové mikroprostředí MeSH
- nádory hlavy a krku metabolismus patologie MeSH
- pohyb buněk účinky léků MeSH
- spinocelulární karcinom metabolismus patologie MeSH
- sulfatasy metabolismus MeSH
- sulfotransferasy * metabolismus MeSH
- vazba proteinů * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Human extracellular 6-O-endosulfatases Sulf-1 and Sulf-2 are the only enzymes that post-synthetically alter the 6-O sulfation of heparan sulfate proteoglycans (HSPG), which regulates interactions of HSPG with many proteins. Oncogenicity of Sulf-2 in different cancers has been documented, and we have shown that Sulf-2 is associated with poor survival outcomes in head and neck squamous cell carcinoma (HNSCC). Despite its importance, limited information is available on direct protein-protein interactions of the Sulf-2 protein in the tumor microenvironment. In this study, we used monoclonal antibody (mAb) affinity purification and mass spectrometry to identify galectin-3-binding protein (LG3BP) as a highly specific binding partner of Sulf-2 in the conditioned media of HNSCC cell lines. We validated their direct interaction in vitro using recombinant proteins and have shown that the chondroitin sulfate (CS) covalently bound to the Sulf-2 influences the binding to LG3BP. We confirmed the importance of the CS chain for the interaction by generating a mutant Sulf-2 protein that lacks the CS. Importantly, we have shown that the LG3BP inhibits Sulf-2 activity in vitro in a concentration-dependent manner. As a consequence, the addition of LG3BP to a spheroid cell culture inhibited the invasion of the HNSCC cells into Matrigel. Thus, Sulf-2 interaction with LG3BP may regulate the physiological activity of the Sulf-2 enzyme as well as its activity in the tumor microenvironment.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019891
- 003
- CZ-PrNML
- 005
- 20241024111014.0
- 007
- ta
- 008
- 241015s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.mcpro.2024.100793 $2 doi
- 035 __
- $a (PubMed)38825040
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Panigrahi, Aswini $u Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA; Clinical and Translational Glycoscience Research Center, Georgetown University, Washington, District of Columbia, USA. Electronic address: aswini.panigrahi@georgetown.edu
- 245 10
- $a Galectin-3-Binding Protein Inhibits Extracellular Heparan 6-O-Endosulfatase Sulf-2 / $c A. Panigrahi, J. Benicky, R. Aljuhani, P. Mukherjee, Z. Nováková, C. Bařinka, R. Goldman
- 520 9_
- $a Human extracellular 6-O-endosulfatases Sulf-1 and Sulf-2 are the only enzymes that post-synthetically alter the 6-O sulfation of heparan sulfate proteoglycans (HSPG), which regulates interactions of HSPG with many proteins. Oncogenicity of Sulf-2 in different cancers has been documented, and we have shown that Sulf-2 is associated with poor survival outcomes in head and neck squamous cell carcinoma (HNSCC). Despite its importance, limited information is available on direct protein-protein interactions of the Sulf-2 protein in the tumor microenvironment. In this study, we used monoclonal antibody (mAb) affinity purification and mass spectrometry to identify galectin-3-binding protein (LG3BP) as a highly specific binding partner of Sulf-2 in the conditioned media of HNSCC cell lines. We validated their direct interaction in vitro using recombinant proteins and have shown that the chondroitin sulfate (CS) covalently bound to the Sulf-2 influences the binding to LG3BP. We confirmed the importance of the CS chain for the interaction by generating a mutant Sulf-2 protein that lacks the CS. Importantly, we have shown that the LG3BP inhibits Sulf-2 activity in vitro in a concentration-dependent manner. As a consequence, the addition of LG3BP to a spheroid cell culture inhibited the invasion of the HNSCC cells into Matrigel. Thus, Sulf-2 interaction with LG3BP may regulate the physiological activity of the Sulf-2 enzyme as well as its activity in the tumor microenvironment.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 12
- $a sulfotransferasy $x metabolismus $7 D015238
- 650 12
- $a vazba proteinů $7 D011485
- 650 _2
- $a dlaždicobuněčné karcinomy hlavy a krku $x metabolismus $x patologie $7 D000077195
- 650 _2
- $a chondroitinsulfáty $x metabolismus $7 D002809
- 650 _2
- $a sulfatasy $x metabolismus $7 D013429
- 650 _2
- $a nádory hlavy a krku $x metabolismus $x patologie $7 D006258
- 650 _2
- $a spinocelulární karcinom $x metabolismus $x patologie $7 D002294
- 650 _2
- $a pohyb buněk $x účinky léků $7 D002465
- 650 _2
- $a nádorové mikroprostředí $7 D059016
- 650 _2
- $a heparansulfát proteoglykany $x metabolismus $7 D019812
- 650 _2
- $a antigeny nádorové $7 D000951
- 650 _2
- $a nádorové biomarkery $7 D014408
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Benicky, Julius $u Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA; Clinical and Translational Glycoscience Research Center, Georgetown University, Washington, District of Columbia, USA
- 700 1_
- $a Aljuhani, Reem $u Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, District of Columbia, USA
- 700 1_
- $a Mukherjee, Pritha $u Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA
- 700 1_
- $a Nováková, Zora $u Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Vestec, Czech Republic
- 700 1_
- $a Bařinka, Cyril $u Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Vestec, Czech Republic
- 700 1_
- $a Goldman, Radoslav $u Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA; Clinical and Translational Glycoscience Research Center, Georgetown University, Washington, District of Columbia, USA; Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, District of Columbia, USA
- 773 0_
- $w MED00007436 $t Molecular & cellular proteomics : MCP $x 1535-9484 $g Roč. 23, č. 7 (2024), s. 100793
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38825040 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111008 $b ABA008
- 999 __
- $a ok $b bmc $g 2202229 $s 1231864
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 23 $c 7 $d 100793 $e 20240601 $i 1535-9484 $m Molecular & cellular proteomics : MCP $n Mol Cell Proteomics $x MED00007436
- LZP __
- $a Pubmed-20241015